Owen A, Spinks J, Meehan A, Robb T, Hardy M, Kwasha D, Wlodarczyk J, Reid C. A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry. Journal of Medical Economics. 2008 Jan;11(2):235–43. doi: 10.3111/13696990802034525.
A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry